ICH E6(R2) vs ICH E6(R3)
Good Clinical Practice’s update — from addendum to a principles-led rewrite.
What a comparison is not
A comparison is SPEQ’s reading of how two published documents differ. Neither is the right answer, it is not a determination of which applies to you, and neither is summarised in a way that replaces reading it.
ICH E6 is the Good Clinical Practice guideline. R2 (2016) added an addendum bringing in risk-based approaches, quality management, and sponsor oversight to the existing structure. R3 is a more fundamental restructure — principles-led, media-neutral, and built for modern trial designs (decentralised elements, diverse data sources) — carrying the risk-based, quality-by-design direction further.
| ASPECT | ICH E6(R2) | ICH E6(R3) |
|---|---|---|
| Form | Original GCP + a 2016 addendum layered on | A restructured, principles-based guideline |
| Core emphasis | Risk-based monitoring, quality management, sponsor oversight (added by addendum) | Quality by design, fit-for-purpose, proportionate approaches throughout |
| Technology stance | Written around traditional trial conduct | Media-neutral; accommodates modern/decentralised data sources |
| Structure | Investigator/sponsor sections + addendum | Principles + annex(es), designed to be adaptable |
| Data governance | Addressed via addendum | Strengthened, source-agnostic data-integrity expectations |
| Direction | Introduced risk-based thinking | Embeds it as the operating model |
E6(R2) is the baseline many current trials and SOPs are built on — risk-based monitoring and quality management added onto the established GCP structure.
E6(R3) is the direction of travel: a principles-led, technology-neutral GCP that expects quality by design and proportionate, fit-for-purpose approaches, and better fits decentralised and data-diverse trials. Plan SOP and training updates for the transition.
R2 bolted modern thinking (risk-based monitoring, quality management, sponsor oversight) onto the old structure; R3 rebuilds GCP around those principles and makes it media-neutral for modern trials. If your quality system still treats monitoring as 100% source data verification, R3 is the prompt to move to risk-based, quality-by-design trial conduct. Track the adoption timeline and update SOPs, training, and oversight models accordingly.
ICH E6(R2) vs ICH E6(R3): frequently asked questions
Common questions on how ICH E6(R2) and ICH E6(R3) differ and when each applies.
What changed from ICH E6(R2) to E6(R3)?
R3 is a structural rewrite rather than an addendum. It is principles-led and media-neutral, embedding quality by design, proportionate/fit-for-purpose approaches, and source-agnostic data governance — carrying forward the risk-based and quality-management concepts R2 introduced via its 2016 addendum.
Does E6(R3) allow decentralised trials?
R3 is written to be technology- and media-neutral, which makes it more accommodating of decentralised elements and diverse data sources than the traditionally-framed R2 text. It focuses on principles and data integrity regardless of how or where data are captured.
What is quality by design in GCP?
Designing quality into a trial from the protocol onward — identifying the factors critical to the reliability of results and participant safety, and focusing effort and monitoring there — rather than inspecting quality in afterwards. R3 makes this the operating model.
Do I need to update SOPs for E6(R3)?
Yes, as adoption proceeds. Expect to revise monitoring, quality-management, sponsor-oversight, and data-governance SOPs and retrain staff to align with R3’s principles-led, risk-based approach, on the timeline set by the adopting regions.